Azacitidine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00928 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 13 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | bulbar polio | KG + DL |
| 2 | refractory cytopenia of childhood | KG + DL |
| 3 | unclassified myelodysplastic syndrome | KG + DL |
| 4 | partial deletion of the long arm of chromosome 5 | KG + DL |
| 5 | aregenerative anemia | KG + DL |
| 6 | severe congenital hypochromic anemia with ringed sideroblasts | KG + DL |
| 7 | 5q35 microduplication syndrome | KG + DL |
| 8 | neuralgic amyotrophy | KG + DL |
| 9 | amyotrophic neuralgia | KG + DL |
| 10 | familial thrombocytosis | KG + DL |
| 11 | reactive thrombocytosis | KG + DL |
| 12 | upper aerodigestive tract neoplasm | KG + DL |
| 13 | chronic myelogenous leukemia, BCR-ABL1 positive | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.